In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model
- PMID: 15304393
- DOI: 10.1182/blood-2004-03-1153
In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model
Abstract
In vitro studies indicate the therapeutic potential of mTOR inhibitors in treating multiple myeloma. To provide further support for this potential, we used the rapamycin analog CCI-779 in a myeloma xenograft model. CCI-779, given as 10 intraperitoneal injections, induced significant dose-dependent, antitumor responses against subcutaneous growth of 8226, OPM-2, and U266 cell lines. Effective doses of CCI-779 were associated with modest toxicity, inducing only transient thrombocytopenia and leukopenia. Immunohistochemical studies demonstrated the antitumor responses were associated with inhibited proliferation and angiogenesis, induction of apoptosis, and reduction in tumor cell size. Although CCI-779-mediated inhibition of the p70 mTOR substrate was equal in 8226 and OPM-2 tumor nodules, OPM-2 tumor growth was considerably more sensitive to inhibition of proliferation, angiogenesis, and induction of apoptosis. Furthermore, the OPM-2 tumors from treated mice were more likely to show down-regulated expression of cyclin D1 and c-myc and up-regulated p27 expression. Because earlier work suggested heightened AKT activity in OPM-2 tumors might induce hypersensitivity to mTOR inhibition, we directly tested this by stably transfecting a constitutively active AKT allele into U266 cells. The in vivo growth of the latter cells was remarkably more sensitive to CCI-779 than the growth of control U266 cells.
Similar articles
-
Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin.Mol Cancer Ther. 2009 Jan;8(1):83-93. doi: 10.1158/1535-7163.MCT-08-0254. Mol Cancer Ther. 2009. PMID: 19139116 Free PMC article.
-
Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.Cancer Res. 2002 Sep 1;62(17):5027-34. Cancer Res. 2002. PMID: 12208757
-
AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells.Oncogene. 2007 Apr 5;26(16):2255-62. doi: 10.1038/sj.onc.1210019. Epub 2006 Oct 2. Oncogene. 2007. PMID: 17016437
-
Mammalian target of rapamycin: a new molecular target for breast cancer.Clin Breast Cancer. 2003 Jun;4(2):126-37. doi: 10.3816/cbc.2003.n.018. Clin Breast Cancer. 2003. PMID: 12864941 Review.
-
mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.Expert Rev Mol Diagn. 2009 Apr;9(3):231-41. doi: 10.1586/erm.09.8. Expert Rev Mol Diagn. 2009. PMID: 19379082 Review.
Cited by
-
Pathway-Directed Therapy in Multiple Myeloma.Cancers (Basel). 2021 Apr 1;13(7):1668. doi: 10.3390/cancers13071668. Cancers (Basel). 2021. PMID: 33916289 Free PMC article. Review.
-
Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies.Br J Haematol. 2009 Jun;145(5):569-80. doi: 10.1111/j.1365-2141.2009.07657.x. Epub 2009 Mar 16. Br J Haematol. 2009. PMID: 19344392 Free PMC article. Review.
-
A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies.Cancer Med. 2021 Mar;10(6):1944-1954. doi: 10.1002/cam4.3672. Epub 2021 Feb 27. Cancer Med. 2021. PMID: 33638305 Free PMC article. Clinical Trial.
-
The c-Myc/AKT1/TBX3 Axis Is Important to Target in the Treatment of Embryonal Rhabdomyosarcoma.Cancers (Basel). 2020 Feb 21;12(2):501. doi: 10.3390/cancers12020501. Cancers (Basel). 2020. PMID: 32098189 Free PMC article.
-
Emerging therapies for multiple myeloma.Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. doi: 10.1517/14728210802676278. Expert Opin Emerg Drugs. 2009. PMID: 19249983 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous